Technology Insight: artificial extracorporeal liver support—how does Prometheus® compare with MARS®?
Peter Krisper* and Rudolf E Stauber
Correspondence *Universitaetsklinik für Innere Medizin, Abteilung für Nephrologie und Hämodialyse, Auenbruggerplatz 27, A-8036 Graz, Austria
Email peter.krisper@klinikum-graz.at
Here, Krisper and Stauber analyze the relative efficiency, clinical outcomes, safety and potential indications of two different 'liver dialysis' systems. Despite their 'experimental' status, the Molecular Adsorbents Recirculating System (MARS®) and Prometheus®, developed by Gambro and Fresenius Medical Care, respectively, are increasingly used to treat patients with severe hepatic failure. Preliminary data are promising, and large-scale randomized trials with the aim of proving a survival benefit are underway.
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
